PrEP for HIV Prevention
Pre-exposure prophylaxis, or PrEP, is an HIV prevention strategy that involves the use of antiretroviral medications by HIV-negative individuals to reduce their risk of HIV infection. PrEP involves taking daily oral tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC), brand name Truvada. Truvada was approved by the U.S. Food and Drug Administration for use as HIV treatment in 2004 and in July 2012, it was approved for use as PrEP. In May 2014, the US Public Health Service released the first comprehensive clinical practice guidelines for PrEP.
Communities across the United States are at varying stages of PrEP awareness and implementation. Achieving the full promise of PrEP will require coordination among many groups, including local and state health departments, healthcare providers, and community-based organizations. To help achieve this promise, NACCHO developed this educational series to (1) increase awareness and knowledge of the role of PrEP for HIV prevention and (2) explore the potential roles for local health departments in delivering PrEP or supporting PrEP delivery as part of comprehensive HIV prevention programs. The educational series is geared towards local health department HIV and STD program managers and staff; however it is intended that the series will also be a useful resource for healthcare providers, community-based organizations, and other key partners in HIV prevention.
The educational series is organized into three modules, each consisting of webcasts (pre-recorded lectures), a webinar, a discussion guide, and supporting resources and tools.
NACCHO’s educational series’ three modules were launched at the beginning of October, November, and December of 2014. Following the release of each module, a live webinar was held to provide an opportunity for participants to ask questions, share information, and connect with their peers. The webinars are archived below.